Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
40.5
USD
|
+1.00%
|
|
+1.55%
|
-12.07%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
352.6
|
554
|
1,643
|
2,466
|
3,503
|
3,056
|
-
|
-
|
Enterprise Value (EV)
1 |
352.6
|
377
|
1,092
|
1,874
|
2,572
|
2,496
|
2,549
|
2,622
|
P/E ratio
|
-8.51
x
|
-19
x
|
-17.6
x
|
-19.1
x
|
-16.9
x
|
-13.7
x
|
-12.2
x
|
-12.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
51.6
x
|
17.2
x
|
89.1
x
|
261
x
|
-
|
1,278
x
|
322
x
|
49.7
x
|
EV / Revenue
|
51.6
x
|
11.7
x
|
59.2
x
|
199
x
|
-
|
1,043
x
|
268
x
|
42.6
x
|
EV / EBITDA
|
-8.32
x
|
-
|
-
|
-14.7
x
|
-12.2
x
|
-11.6
x
|
-11.1
x
|
-12
x
|
EV / FCF
|
-60
x
|
-7.43
x
|
-15.3
x
|
-18.5
x
|
-17
x
|
-11.7
x
|
-15
x
|
-10.8
x
|
FCF Yield
|
-1.67%
|
-13.5%
|
-6.55%
|
-5.41%
|
-5.87%
|
-8.57%
|
-6.65%
|
-9.27%
|
Price to Book
|
-
|
-
|
-
|
3.42
x
|
3.74
x
|
4.21
x
|
6.24
x
|
4.75
x
|
Nbr of stocks (in thousands)
|
26,896
|
36,023
|
52,605
|
62,544
|
76,045
|
75,463
|
-
|
-
|
Reference price
2 |
13.11
|
15.38
|
31.24
|
39.43
|
46.06
|
40.50
|
40.50
|
40.50
|
Announcement Date
|
3/9/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.829
|
32.17
|
18.44
|
9.434
|
-
|
2.392
|
9.495
|
61.52
|
EBITDA
1 |
-42.39
|
-
|
-
|
-127.5
|
-210.5
|
-215.3
|
-229.9
|
-219.1
|
EBIT
1 |
-42.82
|
-31.3
|
-78.99
|
-129.1
|
-214.1
|
-242.1
|
-284.9
|
-293.2
|
Operating Margin
|
-627.02%
|
-97.31%
|
-428.45%
|
-1,368.91%
|
-
|
-10,120.98%
|
-3,000.3%
|
-476.62%
|
Earnings before Tax (EBT)
1 |
-41.62
|
-29.09
|
-78.89
|
-125.3
|
-182.7
|
-217.6
|
-270.9
|
-285.8
|
Net income
1 |
-40.03
|
-28.01
|
-77.09
|
-124.9
|
-182.4
|
-219.6
|
-259.9
|
-278.1
|
Net margin
|
-586.13%
|
-87.09%
|
-418.11%
|
-1,324.32%
|
-
|
-9,178.11%
|
-2,737.46%
|
-451.97%
|
EPS
2 |
-1.540
|
-0.8100
|
-1.770
|
-2.060
|
-2.730
|
-2.960
|
-3.333
|
-3.199
|
Free Cash Flow
1 |
-5.872
|
-50.76
|
-71.55
|
-101.3
|
-150.9
|
-213.8
|
-169.4
|
-243
|
FCF margin
|
-85.99%
|
-157.81%
|
-388.09%
|
-1,074.03%
|
-
|
-8,939.09%
|
-1,784.06%
|
-394.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
8.124
|
3.737
|
8.766
|
0.536
|
0.132
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.378
|
-
|
EBITDA
1 |
-
|
-
|
-16.99
|
-29.94
|
-37.77
|
-42.82
|
-48.7
|
-55.02
|
-53.95
|
-52.84
|
-52.77
|
-53.42
|
-54.07
|
-44.05
|
-
|
EBIT
1 |
-15.6
|
-24.84
|
-17.37
|
-30.32
|
-38.13
|
-43.33
|
-49.05
|
-55.62
|
-55.68
|
-53.7
|
-56.2
|
-59.47
|
-63.66
|
-65.3
|
-57.91
|
Operating Margin
|
-192%
|
-664.65%
|
-198.14%
|
-5,655.78%
|
-28,884.85%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,746.04%
|
-
|
Earnings before Tax (EBT)
1 |
-15.65
|
-25.08
|
-20.06
|
-31.2
|
-37.74
|
-36.26
|
-41.44
|
-47.68
|
-48.62
|
-44.95
|
-49.88
|
-53.28
|
-57
|
-57.92
|
-50.68
|
Net income
1 |
-15.08
|
-25.08
|
-19.37
|
-31.16
|
-37.15
|
-37.4
|
-41.73
|
-47.46
|
-48.46
|
-44.74
|
-50.36
|
-53.56
|
-57.64
|
-59.24
|
-50.68
|
Net margin
|
-185.66%
|
-671.05%
|
-220.98%
|
-5,813.06%
|
-28,143.94%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,491.44%
|
-
|
EPS
2 |
-0.3600
|
-0.4800
|
-0.3500
|
-0.5500
|
-0.5700
|
-0.5700
|
-0.6300
|
-0.7200
|
-0.7300
|
-0.6400
|
-0.6706
|
-0.7103
|
-0.7598
|
-0.7774
|
-0.7450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/1/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/1/23
|
5/9/23
|
8/9/23
|
11/8/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
177
|
552
|
592
|
931
|
560
|
507
|
434
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.87
|
-50.8
|
-71.6
|
-101
|
-151
|
-214
|
-169
|
-243
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-19.7%
|
-22.1%
|
-25.7%
|
-36.7%
|
-48%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-18.8%
|
-21.2%
|
-25.4%
|
-40.3%
|
-45.8%
|
Assets
1 |
-
|
-
|
-
|
663.1
|
859.5
|
863
|
645.4
|
606.9
|
Book Value Per Share
2 |
-
|
-
|
-
|
11.50
|
12.30
|
9.620
|
6.490
|
8.520
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-1.630
|
-2.170
|
-2.730
|
-2.700
|
-
|
Capex
1 |
1.24
|
2.64
|
2.05
|
2.89
|
5.62
|
3.73
|
3.83
|
4.1
|
Capex / Sales
|
18.16%
|
8.2%
|
11.12%
|
30.68%
|
-
|
156.06%
|
40.37%
|
6.66%
|
Announcement Date
|
3/9/20
|
3/1/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
40.5
USD Average target price
57.44
USD Spread / Average Target +41.83% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.07% | 3.06B | | -2.31% | 103B | | +0.56% | 95.28B | | +0.58% | 22.15B | | -17.37% | 21.02B | | -8.24% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|